Introduction
T h e selective delivery of newly synthesized lysosomal enzymes to the lysosome is an essential process in the functional maturation of lysosomes that involves specific recognition and segregation events. During their biosynthesis, soluble acid hydrolases acquire mannose 6-phosphate (Man-6-P) residues on their N-linked oligosaccharides by the action of a phosphotransferase. The ability of the phosphotransferase to recognize a protein determinant which is common to lysosomal enzymes provides the specificity required for the subsequent segregation of lysosomal enzymes from secretory proteins [ 1-51. In the Golgi, phosphomannosyl residues serve as high-affinity ligands for binding to two distinct mannose 6-phosphate receptors (MPRs), the insulin-like growth factor Wcationindependent MPR (IGF-II/CI-MPR) and the cation-dependent MPR (CD-MPR). The removal of acid hydrolases from the secretory pathway occurs when the resulting receptor-lysosomal enzyme complex is transported from the Golgi to an acidified endosomal compartment. T h e low pH of this endosomal compartment induces the dissociation of the complex. T h e released lysosomal enzymes are then packaged into lysosomes while the receptors either return to the Golgi to repeat the process or move to the plasma membrane where, at least for the IGF-II/CI-MPR, they function to internalize exogenous ligands . The importance of this phosphomannosyldependent targeting pathway is borne out by the observation that patients with I-cell disease (mucolipidosis I I) or pseudo-Hurler polydystrophy (mucolipidosis 111) have elevated levels of acid hydrolases in their serum due to a deficiency of the phosphotransferase [9-1 11. This article reviews the recent findings concerning the structural determinants of the IGF-II/CI-MPR that are involved in binding lysosomal enzymes.
IGF-II/CI-MPR structure
The approx. 300 kDa IGF-II/CI-MPR is a multifunctional transmembrane glycoprotein that binds IGF-11, a non-glycosylated polypeptide hormone, and Man-6-P-containing ligands with high affinity [12, 13] . T h e IGF-II/CI-MPR is found in the vast majority of higher eukaryotic cell types and a comparison of its cDNA clones from bovine, human, rat and mouse tissues indiAbbreviations used: Man-b-P, mannose &phosphate;
cates that the is highly conserved. How-MPR, mannose &phosphate receptor; IGF-II/CIever, the overall quaternary structure of this large MPR, insulin-like growth factor II/cation-independent receptor remains questionable since hydromannose 6-phosphate receptor; CD-MPR, cationdynamic measurements are consistent with it dependent mannose 6-phosphate receptor. 38 . Particularly striking is the conserved positioning of cysteine residues that is shared among the 15 domains, the majority of which contain eight cysteine residues. This alignment of cysteine residues has led to a prediction of the disulphide bonding pattern of the receptor which is based on the assumption that all disulphide bonds are formed within each repeating domain and thus implicates a similar tertiary structure for each of the 15 domains [16] . T h e presence of numerous intrachain disulphide bonds is supported by the observation that the receptor's electrophoretic mobility on SDS-polyacrylamide gels decreases significantly under reducing conditions [17] . Only one of the 15 domains contains a sequence which can be found in other known proteins: domain 13 contains a 43-residue insertion that is similar to the type I1 sequence found in fibronectin, factor XI1 and a bovine seminal fluid protein. Although the type I1 sequence has been implicated in binding collagen [18] , the functional significance of this sequence in the IGF-II/CI-MPR is unknown.
Homology to the CD-MPR
An analysis of cell lines which lack the IGF-II/ CI-MPR but are capable of maintaining significant levels of intracellular lysosomal enzymes led to the discovery of a second MPR, the CD-MPR [19] . T h e CD-MPR has now been cloned from several species and the genes for the two MPRs have been localized to different chromosomes [20, 21] . The bovine CD-MPR is also a membrane glycoprotein but, in contrast to the IGF-11/ CI-MPR, it has an apparent molecular mass of 46 kDa, exhibits no detectable binding to IGF-I1 [22] and has optimal Man-6-P binding in the presence of divalent cations [23] . However, cation dependency appears to be a speciesspecific phenomenon since the presence or absence of divalent cations has little effect on the binding capabilities of the human CD-MPR [24] . The bovine CD-MPR consists of a 28-residue amino-terminal signal sequence, a 159-residue extracytoplasmic domain which shares significant sequence identities (14-28%) with each of the 15 repeating domains of the IGF-II/CI-MPR, a single 25-residue transmembrane region and a 67-residue carboxyl-terminal domain [25] . In addition, the location of each of the six cysteine residues in the extracytoplasmic domain of the CD-MPR aligns with the conserved positions of the IGF-II/CI-MPR's cysteine residues. Thus, the overall sequence similarities observed between the IGF-II/CI-MPR and the CD-MPR suggest that the two receptors: (i) arose from a common ancestral gene, (ii) exhibit a similar tertiary structure in their extracytoplasmic domains and (iii) share a common function (i.e., a high-affinity binding of phosphomannosyl residues).
Lysosomal enzyme binding properties
In addition to soluble lysosomal enzymes, other Man-6-P-containing proteins, such as transforming growth factor-B1 precursor "261, proliferin [27] , Herpes simplex virus glycoprotein D [28] and thyroglobulin [29] , have been identified that bind to the IGF-II/CI-MPR. However, most of the studies designed to analyse the binding specificities of the IGF-I I/CI-MPR have been performed using either lysosomal enzymes or oligosaccharides derived from lysosomal enzymes as the ligand. The IGF-II/CI-MPR displays optimal ligand binding at pH 5.7-6.3 and no detectable binding below pH 5 [30, 31] , which is compatible with its function of releasing ligands in the acidic environment of the endosome. The receptor also retains phosphomannosyl binding capabilities at neutral pH, which is consistent with its ability to bind and internalize lysosomal enzymes at the cell surface. Inhibition studies using chemically synthesized oligomannosides or neoglycoproteins demonstrated that the presence of the phosphomonoester Man-6-P at a terminal position is the major determinant of receptor binding. In addition, these studies showed that linear mannose sequences which contained a terminal Man-6-P linked u1,2 to the penultimate mannose were the most potent inhibitors [31, 32] ,
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suggesting that the IGF-IKI-MPR binds an extended oligosaccharide structure which includes the Man-6-Pa1,ZMan sequence. In a complementary study, affinity measurements using monosaccharides which differed from Man-6-P by a single substituent demonstrated that the phosphate group and the axial 2-hydroxyl of mannose are critical for receptor binding [33] .
The existence of significant sequence homologies between the CD-MPR's extracytoplasmic region and each of the 15 repeating domains of the IGF-II/CI-MPR, together with the observations that the CD-MPR binds 1 mol of Man-6-P per polypeptide chain [33] and requires the expression of only its extracytoplasmic domain for phosphomannosyl binding activity [34, 35] , has led to the hypothesis that the IGF-II/CI-MPR contains 15 Man-6-P binding sites. However, equilibrium dialysis experiments revealed that the IGF-II/CI-MPR binds only 2 mol of the monovalent ligand Man-6-P or 1 mol of a diphosphorylated oligosaccharide per polypeptide chain [30] , thus disproving the theory that the IGF-II/CI-MPR represents a gene that has duplicated its carbohydrate binding motif numerous times. Additional studies have shown that diphosphorylated oligosaccharides bind to the receptor with an affinity similar to that of lysosomal enzymes (Kd = 2 x M) and much greater than that of Man-6-P ( & = 7 x 1OP6M) [30] , while neoglycoproteins containing multiple pentamannosyl phosphate residues bind the IGF-II/CI-MPR with an affinity essentially no different to that of an oligosaccharide with two phosphomonoesters [36, 37] . These results indicate that the presence of only two Man-6-P binding sites per functional receptor is sufficient to explain the high-affinity binding of lysosomal enzymes to the IGF-II/CI-MPR. Binding studies using Dictyostelium discoideum lysosomal enzymes, which contain methylated phosphodiesters rather than phosphomonoesters on their N-linked oligosaccharides, gave rise to an intriguing observation. Although phosphodiestercontaining oligosaccharides bind to the receptor at a much lower affinity than oligosaccharides containing phosphomonoesters, intact D. discoideum lysosomal enzymes bind to the IGF-II/CI-MPR at an affinity similar to that of mammalian lysosomal enzymes [30, 38] . One interpretation of these results is that multiple interactions of the weakly binding phosphodiester-containing oligosaccharides are required for the observed highaffinity binding of D. discoideum acid hydrolases to the IGF-II/CI-MPR. The existence of the IGF-II/CI-MPR in an oligomeric state would greatly facilitate these types of multivalent interactions with lysosomal enzymes, many of which are oligomeric themselves and contain a number of phosphorylated oligosaccharides.
Structural determinants of Man-6-P binding
Several recent advances have been made in identifymg structural determinants of the IGF-II/CI-MPR that are critical for Man-6-P binding. An earlier study, in which the receptor that had been either synthesized in the presence of tunicamycin or enzymically deglycosylated with endo-P-N-acetylglucosaminidase H was shown to be capable of binding phosphomannan, indicated that the N-linked oligosaccharides of the IGF-II/ CI-MPR do not play a direct role in binding phosphomannosyl residues [ 171. Several recent studies have focused on a characterization of the size and location of the two Man-6-P binding sites of the IGF-II/CI-MPR. Chemical crosslinking studies using iodinated Man-6-P-containing ligands plus tryptic fragments of the receptor resulted in the radiolabelling of four peptides and, based on the size of these tryptic fragments (15-27 kDa), it was suggested that one to two repeating domains of the IGF-II/CI-MPR comprise a Man-6-P binding site [39] . T o determine the location of the two Man-6-P binding sites in the linear sequence of the IGF-II/CI-MPR, Nterminal sequence analysis of proteolytic fragments of the receptor purified by pentamannosyl phosphate-agarose affinity chromatography was performed, in addition to an analysis of truncated forms of the receptor generated by site-directed mutagenesis. The results of these experiments demonstrated that one Man-6-P binding site is located at the amino terminus encompassing domains 1-3 while the second Man-6-P binding site is located in the middle of the extracytoplasmic region encompassing domains 7-9 [40, 41] . These results are consistent with the observation that the best alignment scores occur between the extracytoplasmic domain of the CD-MPR and domains 3, 5 and 9 of the IGF-II/CI-MPR [16] .
Further studies have been performed to identify amino acid residues of the MPRs that are essential for Man-6-P binding. Chemical modification of the human CD-MPR followed by affinity chromatography of the modified receptors on phosphomannan-Sepharose suggested that utilizing site-directed mutagenesis indicated that HisI3' and Arg13' of the human CD-MPR play essential roles in Man-6-P binding. A comparison of the bovine, human and mouse CD-MPR sequences revealed that ArgI3' is a conserved residue. T o determine whether this arginine is important for Man-6-P binding in a species other than human, this conserved arginine residue in the bovine CD-MPR was changed to either an alanine or a lysine residue and the mutants were analysed by pentamannosyl phosphate-agarose affinity chromatography. As observed with the human CD-MPR, both of these mutations resulted in a >97% loss in the binding activity of the bovine CD-MPR [41]. The sequence similarities observed between the two receptors have prompted the proposal that amino acid residues necessary for Man-6-P binding would be conserved between the ligand binding sites of the two MPRs. Additional sequence analyses revealed that ArgI3' of the CD-MPR was conserved in domains 3, 5, 9 and 13 of the IGF-II/CI-MPR [16] . Since the two Man-6-P binding sites are located within domains 1-3 and 7-9, the conserved arginine residues in domain 3 (Arg43s) and domain 9 (Arg1j3') ( Figure 1) were targeted for site-directed mutagenesis. Replacement of ArgJ35 with either alanine or the charge-conservative residue, lysine, in a construct encoding the amino-terminal binding site (domains 1-3) of the IGF-II/CI-MPR resulted in the loss of ligand were performed in a construct encoding the second Man-6-P binding site (domains 5-9). Taken together, these results indicate that the presence of a guanidinium group, rather than a positive charge, at positions 435 and 1334 is essential for high-affinity Man-6-P binding by
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the amino-terminal and second Man-6-P binding sites, respectively, of the bovine IGF-II/CI-MPR. In addition, the ability of constructs encoding domains 1-3 or domains 5-9 to bind to a Man-6-P-containing affinity resin demonstrates that the amino-terminal and second Man-6-P binding site of the receptor are capable of recognizing phosphomannosyl residues independently of one another.
Conclusions
Significant advances have been made in characterizing the two Man- 6 We are interested in the function of galectin-carbohydrate interactions during mammalian development. T h e fact that carbohydrate residues may be important during embryogenesis was first inferred from their rapid and permanent modulation at various stages of development [15] . their mechanism of action is unclear, it has long been proposed that galectins could be among the
